- Name: Mu-Yan Cai
- Title: Associate Professor and Deputy Director
- Email: caimy@sysucc.org.cn
- Phone:
Profile
Dr. Cai received his MD from Sun Yat-sen University. He completed his postgraduate training in pathology at Sun Yat-sen University Cancer Center and postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School. He is currently an associated professor in the Department of Pathology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He has extensive experience and expertise in the pathological diagnosis of gastrointestinal oncology and lymphoma. His research interest is studying the mechanism of DNA repair deficiency in tumor targeted-therapy and identifying the novel biomarker for tumor pathological diagnosis. He is the recipient of Outstanding Young Talents of Sun Yat-sen University Cancer Center, Guangdong Outstanding Young Medical Talents and Guangdong Natural Science Funds for Distinguished Young Scholar. He has also received various grants from the National Key R&D Program of China, National Natural Science Foundation of Science and provincial level government, and has participated in several international and national cooperation projects. Dr. Cai has published more than 50 papers in some celebrated journal such as GUT, IEEE Trans Cybern, Protein & Cell, Cell Rep, Oncogene, Ebiomedicine, etc.
Interests
The pathological diagnosis of lymphoma and gastrointestinal cancers; DNA damage and repair in tumor targeted-therapy
Education
M.D. Sun Yat-sen University, China, 2000-2005
Master Degree in Pathology, Sun Yat-sen University, China, 2008-2010.
Ph.D in Oncology, Sun Yat-sen University, China, 2012-014.
Publications
Selected publications
1. Cai MY, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, Shapiro GI, Parmar K, Kozono D, D'Andrea AD*. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in double-strand break end resection. Cell Rep. 2020;30(7):2402-2415.e5.
2. Wang X, Chen H*, Gan C, Lin H, Dou Q, Tsougenis E, Huang Q, Cai M*, Heng PA. Weakly Supervised Deep Learning for Whole Slide Lung Cancer Image Analysis. IEEE Trans Cybern. 2020;50(9):3950-3962.
3. Zhang C§, Wei S§, Sun WP§, Teng K, Dai MM, Wang FW, Chen JW, Ling H, Ma XD, Feng ZH, Duan JL, Cai MY*, Xie D*. Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma. Theranostics. 2020;10(20):9066-9082.
4. Wei S§, Dai M§, Zhang C§, Teng K, Wang F, Li H, Sun W, Feng Z, Kang T, Guan X, Xu R, Cai M*, Xie D*. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. Protein Cell. 2020 Aug 3. (Online ahead of print)
5. Cai MY§, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. EZH2 Protein: a Promising Immunomarker Useful for the Detection of Hepatocellular Carcinoma in Liver Needle Biopsies. Gut. 2011; 60(7):967-976.
6. Zhang YJ§, Chen JW§, He XS§, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY*. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. EBioMedicine. 2018;28:62-69.
7. Zhu W§, Cai MY§,Tong ZT§, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut. 2012; 61(4):562-575.
8. Zheng F§, Liao YJ§, Cai MY§, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012; 61(2):278-289.
9. Tong ZT§, Cai MY§，Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, Kung HF, Xie D. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012; 31(5):583-594.
10. Cai MY§, Hou JH§, Rao HL§, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX, Xie D. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011; 17(1-2):12-20.
Updated September 2020 by International Office, Sun Yat-sen University Cancer Center
1. Cai MY, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, Shapiro GI, Parmar K, Kozono D, D'Andrea AD*. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in double-strand break end resection. Cell Rep. 2020;30(7):2402-2415.e5.
2. Wang X, Chen H*, Gan C, Lin H, Dou Q, Tsougenis E, Huang Q, Cai M*, Heng PA. Weakly Supervised Deep Learning for Whole Slide Lung Cancer Image Analysis. IEEE Trans Cybern. 2020;50(9):3950-3962.
3. Zhang C§, Wei S§, Sun WP§, Teng K, Dai MM, Wang FW, Chen JW, Ling H, Ma XD, Feng ZH, Duan JL, Cai MY*, Xie D*. Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma. Theranostics. 2020;10(20):9066-9082.
4. Wei S§, Dai M§, Zhang C§, Teng K, Wang F, Li H, Sun W, Feng Z, Kang T, Guan X, Xu R, Cai M*, Xie D*. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. Protein Cell. 2020 Aug 3. (Online ahead of print)
5. Cai MY§, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. EZH2 Protein: a Promising Immunomarker Useful for the Detection of Hepatocellular Carcinoma in Liver Needle Biopsies. Gut. 2011; 60(7):967-976.
6. Zhang YJ§, Chen JW§, He XS§, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY*. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. EBioMedicine. 2018;28:62-69.
7. Zhu W§, Cai MY§,Tong ZT§, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut. 2012; 61(4):562-575.
8. Zheng F§, Liao YJ§, Cai MY§, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012; 61(2):278-289.
9. Tong ZT§, Cai MY§，Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, Kung HF, Xie D. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012; 31(5):583-594.
10. Cai MY§, Hou JH§, Rao HL§, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX, Xie D. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011; 17(1-2):12-20.
Updated September 2020 by International Office, Sun Yat-sen University Cancer Center